econintersect.com
       
  

FREE NEWSLETTER: Econintersect sends a nightly newsletter highlighting news events of the day, and providing a summary of new articles posted on the website. Econintersect will not sell or pass your email address to others per our privacy policy. You can cancel this subscription at any time by selecting the unsubscribing link in the footer of each email.



posted on 15 May 2016

Another Study Finds Link Between Pharma Money And Brand-name Prescribing

Special Report from ProPublica

-- this post authored by Ryann Grochowski Jones

The findings, by researchers at Harvard Medical School, are in line with a similar analysis done by ProPublica in March.

A group of researchers at Harvard Medical School has found that medical industry payments to physicians in Massachusetts are associated with higher rates of prescribing brand-name drugs that treat high cholesterol.

The study's finding, published today in JAMA Internal Medicine, is in line with a ProPublica analysis and story from March, which showed that physicians who receive industry money tend to prescribe higher rates of brand-name drugs - and thus, lower rates of similarly effective, more affordable generic drugs - when compared to peers.

An aim of the study, said lead author Dr. James S. Yeh, was to determine and reduce any industry influence that could produce bad behavior.

Yeh said:

"You want your doctors to be objective rather than doing something because there is a financial gain, be it subconscious or conscious. That's not the way we should be doing medicine."

Yeh added that not all industry relationships with physicians are problematic. Often pharmaceutical companies fund large research projects that could produce advances in medical care.

The Harvard study concluded that physicians' rate of prescribing brand-name statins - the category of drugs that treat high cholesterol - increased by 0.1 percent for every $1,000 in industry money received. Under $2,000 in payments, there was no significant increase in brand-name prescribing.

A 0.1 percent increase in brand-name prescribing might not seem like much, but the study notes that brand-name statins cost two to four times wholesale as much as generics and that cost is an important factor in patient health outcomes. Patients are less likely to keep taking drugs that are more expensive.

Both ProPublica and the Harvard researchers were careful not to assign a causal relationship between payments and brand-name prescribing because there's a lot that the data alone can't show - for instance, why a doctor chose a certain drug, or the list of preferred drugs used by a patient's insurer. It's also possible that pharmaceutical companies market their drugs more to doctors who are already high brand-name prescribers.

Yeh, a research fellow at Brigham and Women's Hospital and Harvard Medical School, said:

"I think the causal relationship is really difficult to determine because there's so many other factors that impact the physician's prescribing behavior."

The Harvard study differs from ProPublica's analysis in a few ways. ProPublica looked at doctors nationwide in the five most populous specialties, using data from the U.S. Centers for Medicare and Medicaid Services' Open Payments program, which included all payments to doctors from drug and device makers in 2014. The Harvard researchers only looked at Massachusetts doctors, using a 2011 physician payment database kept by the state's department of health.

Also, ProPublica focused on overall brand-name prescribing rates, not just for statins. The researchers chose statins because they are frequently prescribed and because there are both generic and brand-name options.

Both analyses used prescribing data from Medicare's Part D program to determine physicians' brand-name prescribing rates - in fact, the Harvard researchers purchased Part D data prepared for analysis by ProPublica. Part D currently provides drug coverage to nearly 41 million seniors and disabled people.

One of Yeh's co-authors, Dr. Aaron Kesselheim, provided feedback on the design of ProPublica's analysis.

>>>>> Scroll down to view and make comments <<<<<<

Click here for Historical News Post Listing










Make a Comment

Econintersect wants your comments, data and opinion on the articles posted.  As the internet is a "war zone" of trolls, hackers and spammers - Econintersect must balance its defences against ease of commenting.  We have joined with Livefyre to manage our comment streams.

To comment, using Livefyre just click the "Sign In" button at the top-left corner of the comment box below. You can create a commenting account using your favorite social network such as Twitter, Facebook, Google+, LinkedIn or Open ID - or open a Livefyre account using your email address.



You can also comment using Facebook directly using he comment block below.





Econintersect Contributors


search_box

Print this page or create a PDF file of this page
Print Friendly and PDF


The growing use of ad blocking software is creating a shortfall in covering our fixed expenses. Please consider a donation to Econintersect to allow continuing output of quality and balanced financial and economic news and analysis.


Take a look at what is going on inside of Econintersect.com
Main Home
Analysis Blog
The Problem With Obamacare Is That It Did Little To Reduce Overall Healthcare Spending
Joan Robinson’s Critique of Marginal Utility Theory
News Blog
Joe Sixpack's Situation in 3Q2016: The Average Joe Is Better Off
Why Are Some People More Delinquent On Loans Than Others? - Part 1
Gravity Returns To San Francisco Housing Market
Violent Bond Selloff: An Eye-Opening Perspective
Infographic Of The Day: Identity Theft: You Should Be Worried
Early Headlines: Russia Hacked GOP, Trump To Drain Energy 'Swamp'?, New Sec'y Of State Candidate, India IP Shrinks, India Has World's New Largest Solar Plant , China GDP Hides Volatility And More
Most Coup Attempts In Recent Years Have Failed
The Global Cost Of Diabetes
The Universities Churning Out The Most Billionaires
Five Amazing Ways Plants Have Created New Technologies
Where U.S. Weekly Wages Go The Furthest
What We Read Today 09 December 2016
How To Stop Using Filler Words Like Um And Uh
Investing Blog
The New Art Of Utility Investing
Investing,com Weekly Wrap-up 09 December 2016
Opinion Blog
Trickle-down Economics, Trump Edition
Looking At Everything: Trump's $1 Trillion Infrastructure Plan
Precious Metals Blog
Silver Prices Rebounded Today: Where They Are Headed
Live Markets
09Dec2016 Market Close: Wall Street Closes On A New High, Trump Sugar High, Crude Prices Testing Resistance, US Dollar Melts Higher
Amazon Books & More






.... and keep up with economic news using our dynamic economic newspapers with the largest international coverage on the internet
Asia / Pacific
Europe
Middle East / Africa
Americas
USA Government



Crowdfunding ....






























 navigate econintersect.com

Blogs

Analysis Blog
News Blog
Investing Blog
Opinion Blog
Precious Metals Blog
Markets Blog
Video of the Day
Weather

Newspapers

Asia / Pacific
Europe
Middle East / Africa
Americas
USA Government
     

RSS Feeds / Social Media

Combined Econintersect Feed
Google+
Facebook
Twitter
Digg

Free Newsletter

Marketplace - Books & More

Economic Forecast

Content Contribution

Contact

About

  Top Economics Site

Investing.com Contributor TalkMarkets Contributor Finance Blogs Free PageRank Checker Active Search Results Google+

This Web Page by Steven Hansen ---- Copyright 2010 - 2016 Econintersect LLC - all rights reserved